Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04223609 · ClinicalTrials.gov registry record · Phase 1
Non-intrusive Detection of Temporary Neurologic Impairment By Opioids
A Phase 1 study of Healthy, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04223609: Completed Phase 1 study of Healthy, sponsored by Mayo Clinic.
NCT04223609 is a Phase 1 study of Healthy that has completed, run by Mayo Clinic. The registered enrollment target is 14 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04223609, a Phase 1 study of Healthy, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Research is being conducted to better understand the physiologic effects (relating to the action of a drug when taken by a healthy person) of opioid use on oculomotor (relating to the motion of the eye) dynamics and to identify the presence of characteristics consistent with a specific drug or class of drugs.
Primary Outcome
Time it takes participants to complete the OCAT measured in seconds.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oxycodone
- DEVICE EyeLink 1000 Plus
- DIAGNOSTIC_TEST Oculo-Cognitive Addition test (OCAT)
- DEVICE VT3mini - Eye Tracking Technology for OEMs
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-02-28 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 1 |
What the finished NCT04223609 record still lists
NCT04223609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT04223609 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT04223609 about?
NCT04223609 is a clinical study titled "Non-intrusive Detection of Temporary Neurologic Impairment By Opioids". Research is being conducted to better understand the physiologic effects (relating to the action of a drug when taken by a healthy person) of opioid use on oculomotor (relating to the motion of the eye) dynamics and to identify the presence of characteristics consistent with a specific drug or class...
What is the current status of trial NCT04223609?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-02-28. Estimated completion is 2022-04-11.
What conditions does trial NCT04223609 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04223609?
The interventions under investigation include: Placebo (DRUG), Oxycodone (DRUG), EyeLink 1000 Plus (DEVICE), Oculo-Cognitive Addition test (OCAT) (DIAGNOSTIC_TEST), VT3mini - Eye Tracking Technology for OEMs (DEVICE).
Who is sponsoring clinical trial NCT04223609?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04223609 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04223609's enrollment target sits among peer trials
14 974th of 1090 higher than 106 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy